Cellectar Biosciences, Inc.
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$25M
Investors
21
Min Invest
$84,400
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
Cellectar Biosciences, Inc. is a Delaware corporation that filed a Form D with the SEC on September 22, 2023 in the Biotechnology industry group. The offering claims Rule 506(b) and covers equity. Cellectar Biosciences, Inc. reported $24,500,000 sold from 21 investors of a $24,500,000 total offering as of the Form D filed September 22, 2023. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $84,400. The Form D names Oppenheimer & Co. Inc. (CRD 249), associated with None as the recipient of sales compensation soliciting in CA, CT, IL, MD, NC, NV, NY, TX. The issuer's address of record is 100 Campus Drive, Florham Park, NJ 07932.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
0
none on file
Critical / warning
0 / 0
0 watch · 0 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
4
closed, lapsed
Investor
- 4 offering timelines: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Item 3 changed on the Form D filed 2023-09-22: 4 related persons added and 3 removed against the filing of 2021-01-08; 10 now listed. The names are in the Terminal feed.
James V. Caruso
Executive Officer, Director · Florham Park, NJ
Chad J. Kolean
Executive Officer · Florham Park, NJ
Jarrod J. Longcor
Executive Officer · Florham Park, NJ
Darrell Shane Lea
Executive Officer · Florham Park, NJ
Andrei Shane Shustov
Executive Officer · Florham Park, NJ
Douglas J. Swirsky
Director · Florham Park, NJ
Asher Alban Chanan-Kahn
Director · Florham Park, NJ
Frederick W. Driscoll
Director · Florham Park, NJ
Stefan D. Loren
Director · Florham Park, NJ
John D. Neis
Director · Florham Park, NJ
Placement Agents and Sales Compensation (Form D)
Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.
Oppenheimer & Co. Inc.CRD 249 on BrokerCheck
Associated broker-dealer: None · NEW YORK, NY · Soliciting in CA, CT, IL, MD, NC, NV, NY, TX
Questions About Cellectar Biosciences, Inc.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Cellectar Biosciences, Inc.?
Cellectar Biosciences, Inc. is a Delaware corporation that filed a Form D with the SEC on September 22, 2023 in the Biotechnology industry group. The filing claims Rule 506(b) for an offering of equity.
Is Cellectar Biosciences, Inc. legit?
AltStreet does not rate legitimacy; it reports the public record. Cellectar Biosciences, Inc. filed a Form D with the SEC on September 22, 2023 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $24,500,000 sold to 21 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Cellectar Biosciences, Inc. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Cellectar Biosciences, Inc. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Cellectar Biosciences, Inc. raised?
Cellectar Biosciences, Inc. reported $24,500,000 sold from 21 investors of a $24,500,000 total offering as of the Form D filed September 22, 2023.
Who can invest in Cellectar Biosciences, Inc.?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $84,400.
What is the minimum investment in Cellectar Biosciences, Inc.?
The Form D lists $84,400 as the minimum investment accepted from any outside investor as of September 22, 2023. Issuers can waive their own minimums, and the figure does not include fees.
Who is selling Cellectar Biosciences, Inc. and how are they paid?
The Form D names Oppenheimer & Co. Inc. (CRD 249), associated with None as the recipient of sales compensation soliciting in CA, CT, IL, MD, NC, NV, NY, TX.
Who is behind Cellectar Biosciences, Inc.?
The Form D lists 10 related persons: James V. Caruso, executive officer, director; Chad J. Kolean, executive officer; Jarrod J. Longcor, executive officer; Darrell Shane Lea, executive officer; Andrei Shane Shustov, executive officer; Douglas J. Swirsky, director; Asher Alban Chanan-Kahn, director; Frederick W. Driscoll, director, and 2 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Cellectar Biosciences, Inc. located?
The issuer's address on its SEC filings is 100 Campus Drive, Florham Park, NJ 07932. Its phone number of record is (608) 441-8120. It is organized under the laws of Delaware.
How long is the Cellectar Biosciences, Inc. offering open?
The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.
What is Cellectar Biosciences, Inc.'s revenue?
The issuer declined to disclose its revenue range on the Form D, which the form permits.
Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.